Insmed (INSM) Income from Continuing Operations (2010 - 2026)
Insmed (INSM) posted quarterly Income from Continuing Operations of 163598000.0 for Q1 2026, up 36.24% year-over-year from 120083601.66 in Q1 2025, and up 50.19% quarter-over-quarter from 328434000.0 in Q4 2025.
Insmed (INSM) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Insmed's Income from Continuing Operations history runs 17 years deep, the most recent figure standing at 163598000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 36.24% year-over-year to 163598000.0; the TTM figure through Mar 2026 stood at 1183719000.0 (down 16.82% YoY), while the FY2025 annual figure was 1276749000.0, down 39.72% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 163598000.0, up from 328434000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 94621000.0 in Q1 2022, with the low at 370001000.0 in Q3 2025.
- The 5-year median for Income from Continuing Operations is 186063000.0 (2023), against an average of 210890470.59.
- The sharpest annual moves came in 2023 and 2026: Income from Continuing Operations slumped 155.92% in 2023, then jumped 36.24% in 2026.
- Insmed's Income from Continuing Operations stood at 160123000.0 in 2022, then retreated by 16.2% to 186063000.0 in 2023, then dropped by 26.62% to 235589000.0 in 2024, then sank by 39.41% to 328434000.0 in 2025, then surged by 50.19% to 163598000.0 in 2026.
- Business Quant data shows INSM's Income from Continuing Operations at 163598000.0 in Q1 2026, 328434000.0 in Q4 2025, and 370001000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -290.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -13.27 Mn |
| Mar 31, 2026 | -163.60 Mn |
| Dec 31, 2025 | -328.43 Mn |
| Sep 30, 2025 | -370.00 Mn |
| Jun 30, 2025 | -321.69 Mn |
| Mar 31, 2025 | -256.57 Mn |
| Dec 31, 2024 | -235.59 Mn |
| Sep 30, 2024 | -220.52 Mn |
| Jun 30, 2024 | -300.57 Mn |
| Mar 31, 2024 | -157.09 Mn |
| Dec 31, 2023 | -186.06 Mn |
| Sep 30, 2023 | -158.93 Mn |
| Jun 30, 2023 | -244.78 Mn |
| Mar 31, 2023 | -159.76 Mn |
| Dec 31, 2022 | -160.12 Mn |
| Sep 30, 2022 | -131.15 Mn |
| Jun 30, 2022 | -95.65 Mn |
| Mar 31, 2022 | -94.62 Mn |
| Dec 31, 2021 | -112.94 Mn |
| Sep 30, 2021 | -112.71 Mn |